Latest Property Portfolio News

Island Pharmaceuticals has secured key regulatory milestones for its antiviral Galidesivir, including FDA confirmation of the Animal Rule pathway and Priority Review Voucher eligibility, while strengthening US biodefense ties and expanding patent protection.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Proteomics International has been granted a Canadian patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma. This milestone strengthens its global intellectual property portfolio and paves the way for commercial expansion in North America.

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

Mesoblast Limited reports a 60% jump in Ryoncil sales for the December quarter, underpinned by a new $125 million financing facility that strengthens its balance sheet and strategic flexibility.

Island Pharmaceuticals has been granted a key US patent for Galidesivir, extending intellectual property protection through 2031 for treating filoviridae viruses including Marburg and Ebola. This milestone aligns with the company’s clinical development strategy and recent FDA regulatory progress.

US Masters Residential Property Group has amended its term loan facility, increasing the interest rate and extending the maturity date to enhance capital management flexibility.

Mesoblast has refinanced its senior debt with a new US$125 million, five-year credit facility that lowers borrowing costs and preserves key assets, positioning the company for strategic growth.

Aeeris Ltd has received a $506,992.50 refundable R&D tax incentive for FY25, fueling advancements in its proprietary Australian Weather And Risk Environment (AWARE) system and AI-driven forecasting tools.

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Region Group reports a $129 million uplift in its investment property portfolio valuation as of December 2025, alongside improved net tangible assets and stable gearing levels.

An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.